GoodRx stock soars after CEO hints at potential TrumpRx partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Morgan Stanley Reiterates Equalweight Rating on GoodRx Holdings Inc. (GDRX) Amid Speculation of TrumpRx
October 2, 2025 4:33 AM EDTMorgan Stanley analyst Craig Hettenbach reiterated an Equalweight rating and $5.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX)
The analyst comments "GDRX traded materially higher today (+19% vs. Russell 2000 +0.2%) on heavy volume (22mn shares or ~10x daily average) following news that the company could potentially partner with TrumpRx. This was discussed during an interview CEO Wendy Barnes had on Fox Business (article). Separately, we view news of an expansion with Kroger (covered by Simeon Gutman) as potentially the more meaningful... More
